HDG1901
Asset
GLP-1 receptor agonist biosimilar stimulating insulin release and regulating glucose.
- Stage
- Phase 3
- Modality
- Peptide
- Target
- GLP1R
- 1
- Indication
- 2
- Trials
- 2
- Developers
Indications
1Type 2 diabetes
Phase 3, Completed, NCT06739044, clinicaltrials.gov, Oct 22, 2026
In the full profile
- Target and mechanism1
- Owner and partners2
- Trials2
- Evidence for its targets2
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.